Drug intelligence / Profile preview

CVD-1301.LH03

Development stage: Preclinical
Lead developer: Converd
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

CVD-1301.LH03 is an oncolytic herpes simplex virus (HSV) therapy being developed by Hangzhou Converd Co., Ltd. for the treatment of cancer. Engineered using Converd's HSV-based oncolytic virus platform, the drug is designed to selectively infect and replicate within tumor cells, causing direct cell lysis (oncolysis). Beyond its direct cytolytic effects, CVD-1301.LH03 is engineered to function as an immuno-stimulator, promoting an inflammatory tumor microenvironment and activating a systemic anti-tumor immune response. As of the latest pipeline reports, the candidate is in the IND (Investigational New Drug) stage of development.

Beyond the preview

Go deeper on CVD-1301.LH03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVD-1301.LH03.

Explore the full profile